DADC
CRSP icon

D.A. Davidson & Co’s CRISPR Therapeutics CRSP Stock Holding History

D.A. Davidson & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Hold
6,324
– – ﹤0.01% 1344
2026
Q1 		$301K Buy
6,324
+353
+6% +$18.6K ﹤0.01% 1350
2025
Q4 		$313K Buy
5,971
+592
+11% +$35.5K ﹤0.01% 1300
2025
Q3 		$349K Buy
+5,379
New +$309K ﹤0.01% 1258
2021
Q4 		– Sell
-2,942
Closed -$329K – 1270
2021
Q3 		$329K Buy
2,942
+356
+14% +$44.7K ﹤0.01% 976
2021
Q2 		$419K Hold
2,586
– – ﹤0.01% 881
2021
Q1 		$315K Buy
+2,586
New +$390K ﹤0.01% 945
2018
Q4 		– Sell
-7,876
Closed -$349K – 1107
2018
Q3 		$349K Sell
7,876
-7,375
-48% -$386K 0.01% 850
2018
Q2 		$896K Sell
15,251
-1
-0% -$57 0.02% 533
2018
Q1 		$697K Sell
15,252
-500
-3% -$20.6K 0.01% 582
2017
Q4 		$370K Buy
+15,752
New +$299K 0.01% 761

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.A. Davidson & Co's CRSP Position: Q2 2026 in Review

D.A. Davidson & Co held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 6,324 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1344.

D.A. Davidson & Co first reported a position in CRSP in Q4 2017 and has held it in 11 quarters since. The position peaked at $896K in Q2 2018. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • D.A. Davidson & Co held 6,324 shares of CRISPR Therapeutics worth $345K as of Q2 2026.
  • D.A. Davidson & Co left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of D.A. Davidson & Co's portfolio in Q2 2026, its #1344 holding.
  • D.A. Davidson & Co first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 11 quarters since.
  • D.A. Davidson & Co's CRISPR Therapeutics position peaked at $896K in Q2 2018.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.